ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium

References

1. 1.↵
   1. Ostrom QT,
   2. Cioffi G,
   3. Gittleman H, et al

   . CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1–100 doi:10.1093/neuonc/noz150 pmid:31675094

   CrossRefPubMed
2. 2.↵
   1. Ryall S,
   2. Tabori U,
   3. Hawkins C

   . Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 2020;8:30 doi:10.1186/s40478-020-00902-z pmid:32164789

   CrossRefPubMed
3. 3.↵
   1. Collins KL,
   2. Pollack IF

   . Pediatric low-grade gliomas. Cancers 2020;12:1152 doi:10.3390/cancers12051152

   CrossRef
4. 4.↵
   1. Broniscer A,
   2. Baker SJ,
   3. West AN, et al

   . Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 2007;25:682–89 doi:10.1200/JCO.2006.06.8213 pmid:17308273

   Abstract/FREE Full Text
5. 5.↵
   1. Sharif S,
   2. Ferner R,
   3. Birch JM, et al

   . Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006;24:2570–75 doi:10.1200/JCO.2005.03.8349 pmid:16735710

   Abstract/FREE Full Text
6. 6.↵
   1. Jones DTW,
   2. Kieran MW,
   3. Bouffet E, et al

   . Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol 2018;20:160–73 doi:10.1093/neuonc/nox141 pmid:29016845

   CrossRefPubMed
7. 7.↵
   1. Banerjee A,
   2. Jakacki RI,
   3. Onar-Thomas A, et al

   . A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 2017;19:1135–44 doi:10.1093/neuonc/now282 pmid:28339824

   CrossRefPubMed
8. 8.↵
   1. Fangusaro J,
   2. Onar-Thomas A,
   3. Young Poussaint T, et al

   . Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20:1011–22 doi:10.1016/S1470-2045(19)30277-3 pmid:31151904

   CrossRefPubMed
9. 9.↵
   1. Fangusaro J,
   2. Onar-Thomas A,
   3. Poussaint TY, et al

   . A phase 2 trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium Study. Neuro Oncol 2021;23:1777–88 doi:10.1093/neuonc/noab047 pmid:33631016

   CrossRefPubMed
10. 10.↵
    1. Fangusaro J,
    2. Witt O,
    3. Hernáiz Driever P, et al

    . Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 2020;21:e305–16 doi:10.1016/S1470-2045(20)30064-4 pmid:32502457

    CrossRefPubMed
11. 11.↵
    1. Jenkinson M,
    2. Beckmann CF,
    3. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Poussaint TY,
    2. Vajapeyam S,
    3. Ricci KI, et al

    . Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 2016;18:725–34 doi:10.1093/neuonc/nov256 pmid:26487690

    CrossRefPubMed
13. 13.↵
    1. Schindelin J,
    2. Arganda-Carreras I,
    3. Frise E, et al

    . Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676–82 doi:10.1038/nmeth.2019 pmid:22743772

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Strimmer K

    . fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 2008;24:1461–62 doi:10.1093/bioinformatics/btn209 pmid:18441000

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Packer RJ,
    2. Pfister S,
    3. Bouffet E, et al

    . Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol 2017;19:750–61 doi:10.1093/neuonc/now209 pmid:27683733

    CrossRefPubMed
16. 16.↵
    1. Ryall S,
    2. Zapotocky M,
    3. Fukuoka K, et al

    . Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 2020;37:569–83 doi:10.1016/j.ccell.2020.03.011 pmid:32289278

    CrossRefPubMed
17. 17.↵
    1. Jones DT,
    2. Kocialkowski S,
    3. Liu L, et al

    . Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009;28:2119–23 doi:10.1038/onc.2009.73 pmid:19363522

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Lassaletta A,
    2. Zapotocky M,
    3. Mistry M, et al

    . Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 2017;35:2934–41 doi:10.1200/JCO.2016.71.8726 pmid:28727518

    CrossRefPubMed
19. 19.↵
    1. Karajannis MA,
    2. Legault G,
    3. Fisher MJ, et al

    . Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 2014;16:1408–16 doi:10.1093/neuonc/nou059 pmid:24803676

    CrossRefPubMed
20. 20.↵
    1. Sievert AJ,
    2. Lang SS,
    3. Boucher KL, et al

    . Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013;110:5957–62 doi:10.1073/pnas.1219232110 pmid:23533272

    Abstract/FREE Full Text
21. 21.↵
    1. Burkhard C,
    2. Di Patre PL,
    3. Schüler D, et al

    . A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 2003;98:1170–74 doi:10.3171/jns.2003.98.6.1170 pmid:12816259

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Collins VP,
    2. Jones DT,
    3. Giannini C

    . Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129:775–78 doi:10.1007/s00401-015-1410-7 pmid:25792358

    CrossRefPubMed
23. 23.↵
    1. Listernick R,
    2. Louis DN,
    3. Packer RJ, et al

    . Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41:143–49 doi:10.1002/ana.410410204 pmid:9029062

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Gauvain KM,
    2. McKinstry RC,
    3. Mukherjee P, et al

    . Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol 2001;177:449–54 doi:10.2214/ajr.177.2.1770449 pmid:11461881

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Koral K,
    2. Mathis D,
    3. Gimi B, et al

    . Common pediatric cerebellar tumors: correlation between cell densities and apparent diffusion coefficient metrics. Radiology 2013;268:532–37 doi:10.1148/radiol.13121362 pmid:23564715

    CrossRefPubMed
26. 26.↵
    1. Jost SC,
    2. Ackerman JW,
    3. Garbow JR, et al

    . Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol 2008;38:1293–99 doi:10.1007/s00247-008-1003-x pmid:18846370

    CrossRefPubMed
27. 27.↵
    1. Yeom KW,
    2. Lober RM,
    3. Andre JB, et al

    . Prognostic role for diffusion-weighted imaging of pediatric optic pathway glioma. J Neurooncol 2013;113:479–83 doi:10.1007/s11060-013-1140-4 pmid:23673514

    CrossRefPubMed
28. 28.↵
    1. Hsu CH,
    2. Lober RM,
    3. Li MD, et al

    . Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab. J Neurooncol 2015;122:491–96 doi:10.1007/s11060-015-1754-9 pmid:25758812

    CrossRefPubMed
29. 29.↵
    1. Payabvash S,
    2. Aboian M,
    3. Tihan T, et al

    . Machine learning decision tree models for differentiation of posterior fossa tumors using diffusion histogram analysis and structural MRI findings. Front Oncol 2020;10:71 doi:10.3389/fonc.2020.00071 pmid:32117728

    CrossRefPubMed
30. 30.↵
    1. Vajapeyam S,
    2. Brown D,
    3. Johnston PR, et al

    . Multiparametric analysis of permeability and ADC histogram metrics for classification of pediatric brain tumors by tumor grade. AJNR Am J Neuroradiol 2018;39:552–57 doi:10.3174/ajnr.A5502 pmid:29301780

    Abstract/FREE Full Text
31. 31.↵
    1. Jaimes C,
    2. Vajapeyam S,
    3. Brown D, et al

    . MR imaging correlates for molecular and mutational analyses in children with diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2020;41:874–81 doi:10.3174/ajnr.A6546 pmid:32381545

    Abstract/FREE Full Text
32. 32.↵
    1. Vajapeyam S,
    2. Brown D,
    3. Billups C, et al

    . Advanced ADC histogram, perfusion, and permeability metrics show an association with survival and pseudoprogression in newly diagnosed diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. AJNR Am J Neuroradiol 2020;41:718–24 doi:10.3174/ajnr.A6499 pmid:32241771

    Abstract/FREE Full Text
33. 33.↵
    1. Sugahara T,
    2. Korogi Y,
    3. Kochi M, et al

    . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60 doi:10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2 pmid:10030650

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Chenevert TL,
    2. Stegman LD,
    3. Taylor JM, et al

    . Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029–36 doi:10.1093/jnci/92.24.2029 pmid:11121466

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Hoyt WF,
    2. Baghdassarian SA

    . Optic glioma of childhood: natural history and rationale for conservative management. Br J Ophthalmol 1969;53:793–98 doi:10.1136/bjo.53.12.793 pmid:5386369

    FREE Full Text
36. 36.↵
    1. Gross AM,
    2. Wolters PL,
    3. Dombi E, et al

    . Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020;382:1430–42 doi:10.1056/NEJMoa1912735 pmid:32187457

    CrossRefPubMed
37. 37.↵
    1. Lévy P,
    2. Bièche I,
    3. Leroy K, et al

    . Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clin Cancer Res 2004;10:3763–71 doi:10.1158/1078-0432.CCR-03-0712 pmid:15173083

    Abstract/FREE Full Text
38. 38.↵
    1. Deliganis AV,
    2. Geyer JR,
    3. Berger MS

    . Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 1996;38:1114–18; discussion 1118–19 doi:10.1097/00006123-199606000-00010 pmid:8727140

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Kornreich L,
    2. Blaser S,
    3. Schwarz M, et al

    . Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol 2001;22:1963–69 pmid:11733333

    Abstract/FREE Full Text
40. 40.↵
    1. Wagner MW,
    2. Hainc N,
    3. Khalvati F, et al

    . Radiomics of pediatric low-grade gliomas: toward a pretherapeutic differentiation of BRAF-mutated and BRAF-fused tumors. AJNR Am J Neuroradiol 2021;42:759–65 doi:10.3174/ajnr.A6998 pmid:33574103

    Abstract/FREE Full Text